0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Cancer of the Nervous System: 2010

Arch Neurol. 2010;67(3):272. doi:10.1001/archneurol.2010.24.
Text Size: A A A
Published online

Extract

In this issue of the Archives, we present a survey of articles that cover the important clinical and basic scientific advances in neuro-oncology during the last 5 years. Clearly, investigators in this field are innovative, and progress is being made on several fronts in understanding the molecular and cellular changes causal of nervous system neoplasm and developing new therapies. The molecular and genetic changes that occur in sequence in converting the normal astrocyte to a grade 4 glioblastoma cell have been elucidated recently and are presented herein. Glioblastomas are produced due to genetic mutations and resultant altered functions, and individuals are associated with increased risk as a result of several genomic polymorphisms. How these various genetic mutations and altered functions and associated polymorphisms are connected remain unknown, but insights are continuing to emerge and are discussed herein. Molecular targets for potential therapy have been proposed based on these findings and are an important advance in eventually finding effective therapy for this most common and malignant brain tumor. Therapy for glioblastomas—including use of temozolomide, 5-aminolevulinic acid for more complete surgical resection, external beam radiation, intensity-modulated radiation therapy, use of antibodies and inhibitors to the epidermal growth factor receptor, antiangiogenesis therapy, immunotherapy, histone deacetylase inhibitors, and gene therapy—are concisely reviewed. A phase 1 clinical trial with ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties when used concurrently with temozolomide and radiotherapy, is reported. O-(2-[18F]-fluoroethyl)-L-tyrosine is a new positron emission tomography tracer that is promising to image and diagnose high-grade gliomas. Primary central nervous system lymphoma is a rare but troubling neoplasm, and, although remissions may be achieved, the tumor relapses in most cases. Primary central nervous system lymphoma is increased significantly in the immune-incompetent person and is the focus of a review. Myelopathies in patients with cancer and new strategies in the management of leptomeningeal metastases are 2 important areas of therapeutic concern and are discussed in detail. An emerging and growing area of related neurological disease in patients with cancer is the paraneoplastic syndromes, and a large database of these patients is presented to provide an overview of the clinical incidence of specific syndromes and therapeutic outcomes. The diagnostic achievement in evaluating paraneoplastic disease by evaluating the cancer detection rate with whole-body positron emission tomography–computed tomography is presented. Positron emission tomography–computed tomography improves detection of cancers when other screening tests are negative in the setting of seropositivity for a neuronal nuclear or cytoplasmic autoantibody marker of cancer.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination
Make the Diagnosis: Cancer, Family History

The Rational Clinical Examination
Original Article: Does This Patient Have a Family History of Cancer?

brightcove.createExperiences();